SCHEDULE: Alyeska Investment Group Discloses 9.9% Stake

Alyeska Investment Group, L.P. and its affiliates reported beneficial ownership of 9.9% of Achieve Life Sciences, Inc.'s common stock as of June 30, 2025.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 4,918,822 shares of Achieve Life Sciences, Inc. common stock.
• This represents 9.9% of the company's outstanding common stock.
• The ownership includes 3,504,333 shares of common stock and warrants to purchase an additional 1,414,489 shares, limited by a 9.9% beneficial ownership cap.
• The percentage calculation is based on an assumed 49,685,072 outstanding common shares as per the Issuer's June 27, 2025 Prospectus.

Sentiment

Score: 5

Explanation: The filing is a neutral regulatory disclosure of beneficial ownership, indicating a passive investment position without expressing positive or negative sentiment about the company's performance or prospects.

Risks

• The beneficial ownership percentage is capped at 9.9% due to warrant terms, limiting potential further accumulation without triggering additional disclosure requirements or changes to the warrant terms.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by Alyeska Investment Group in Achieve Life Sciences, a common occurrence in the investment landscape where institutional investors take positions in publicly traded companies. It does not suggest any specific industry trend beyond general market investment activity.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence or liquidity depending on future actions.

Key Dates

Recommendation

The Schedule 13G filing indicates a significant passive stake by Alyeska Investment Group in Achieve Life Sciences. While this signals institutional interest, the filing itself does not provide new fundamental information about the company's operations, financial performance, or strategic direction to warrant a strong buy or sell recommendation. Investors should 'hold' and await further operational or financial updates from Achieve Life Sciences.

Keywords

Achieve Life Sciences, Alyeska Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Disclosure, Institutional Investor, Biotechnology, Pharmaceuticals